A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
Active, not recruiting · Phase 2 · NCT05139602
Conditions: Hidradenitis Suppurativa
At a glance
- Research payments reported, 2025
- $316,732
- U.S. investigators named
- 16
- Sites paid
- 17
- Planned or actual enrollment
- 210
About the trial
- Sponsor
- AbbVie
- Tested
- Lutikizumab (biological), Placebo (drug)
- Dates
- Started 2021-12-28; completion 2027-12
- Results posted
- Not yet
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. Despite the clinical benefit anti-tumor necrosis factor (TNF) therapy offers to patients with HS, there remains a significant unmet medical need for patients who fail to achieve adequate benefit with anti-TNF therapy. This study will compare lutikizumab (ABT-981) versus placebo for the treatment of adult participants with moderate to severe HS who have failed anti-TNF therapy. Lutikizumab (ABT-981) is an investigational drug being developed for the tre…
From ClinicalTrials.gov, last updated 2026-02-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $316,732 in research payments for this study in 2025 (159 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Dowling B. Stough IV, MD Dermatology · Hot Springs, AR
- Lindsay S. Ackerman, MD Dermatology · Phoenix, AZ
- Aaron Mangold, M.D. Dermatology · Scottsdale, AZ
- Navid Ezra, M.D. Dermatology · Thousand Oaks, CA
- Michelle T. Pelle, M.D. Dermatology · San Diego, CA
- Gregory L. Simpson, M.D. Dermatology · Fresno, CA
- Christopher D. Ewanowski, M.D. Dermatology · Lutz, FL
- Scott A. Fretzin, M.D. Dermatology · Indianapolis, IN
- Alexandra B. Kimball, MD MPH Dermatology · Boston, MA
- Ali Moiin, MD Dermatology · Troy, MI
- Milan J. Anadkat, MD Dermatology · Saint Louis, MO
- Melody Stone, MD Dermatology · Saint Joseph, MO
- Jerry Bagel, MD Dermatology · East Windsor, NJ
- Saakshi Khattri, MD Dermatology · New York, NY
- Mary M. Morgan, M.D. Dermatology · Broken Arrow, OK
- Alma M. Cruz Santana, MD Dermatology · Carolina, PR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mayo Clinic Hospital, AZ $57,078
- Essential Medical Research LLC $47,438
- Clinical Trials Research Institute $42,843
- Sdg Dermatology PC $28,261
- Beth Israel Deaconess Medical Center, MA $25,680
- Medisearch Clinical Trials $17,034
- Revival Research Institute LLC $16,740
- Icahn School of Med at Mt Sinai $16,696
- Apex Clinical Trials LLC $14,315
- $13,404
- Medderm Corporation $8,346
- Alma M Cruz-Santana $7,924
- Washington University $5,814
- Dawes Fretzin Clinical Research Group LLC $5,461
- Southwest Skin Specialists LLC $3,562
- Dawes Fretzin Clinical Research $3,417
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $1,720
- Burke Pharmaceutical Research $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.